- Home
- STSS vs MBIO Comparison
STSS vs MBIO Comparison
Compare STSS & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STSS
- MBIO
- Stock Information
- Founded
- STSS 2017
- MBIO 2015
- Country
- STSS United States
- MBIO United States
- Employees
- STSS N/A
- MBIO N/A
- Industry
- STSS Medical/Dental Instruments
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- STSS Health Care
- MBIO Health Care
- Exchange
- STSS Nasdaq
- MBIO Nasdaq
- Market Cap
- STSS 5.5M
- MBIO 4.7M
- IPO Year
- STSS 2022
- MBIO N/A
- Fundamental
- Price
- STSS $5.73
- MBIO $2.65
- Analyst Decision
- STSS
- MBIO
- Analyst Count
- STSS 0
- MBIO 0
- Target Price
- STSS N/A
- MBIO N/A
- AVG Volume (30 Days)
- STSS 149.1K
- MBIO 17.4M
- Earning Date
- STSS 08-13-2025
- MBIO 08-12-2025
- Dividend Yield
- STSS N/A
- MBIO N/A
- EPS Growth
- STSS N/A
- MBIO N/A
- EPS
- STSS N/A
- MBIO N/A
- Revenue
- STSS N/A
- MBIO N/A
- Revenue This Year
- STSS N/A
- MBIO N/A
- Revenue Next Year
- STSS N/A
- MBIO N/A
- P/E Ratio
- STSS N/A
- MBIO N/A
- Revenue Growth
- STSS N/A
- MBIO N/A
- 52 Week Low
- STSS $3.36
- MBIO $0.89
- 52 Week High
- STSS $2,224.20
- MBIO $24.00
- Technical
- Relative Strength Index (RSI)
- STSS 45.95
- MBIO 61.22
- Support Level
- STSS $5.51
- MBIO $2.62
- Resistance Level
- STSS $5.95
- MBIO $3.68
- Average True Range (ATR)
- STSS 0.32
- MBIO 0.59
- MACD
- STSS 0.20
- MBIO 0.18
- Stochastic Oscillator
- STSS 66.25
- MBIO 28.77
About STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes designed to eliminate potentially infectious and accidental needlestick injuries.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.